The recommended dosage for the Breztri Aerosphere inhaler is two inhalations once daily [1]. This dosage is intended for patients with chronic obstructive pulmonary disease (COPD) [1].
How should I use the Breztri inhaler?
To use the Breztri Aerosphere inhaler, patients should first prime the device by shaking it well and spraying four times into the air. Then, they should exhale as completely as possible. Next, they should place the mouthpiece between their lips and close them tightly, ensuring they do not block the air vents. Finally, they should inhale steadily and deeply for three seconds, hold their breath for five seconds, and then exhale [1]. After use, it is recommended to rinse the mouth with water and spit it out, without swallowing, to help prevent thrush [1].
What is Breztri Aerosphere?
Breztri Aerosphere is a combination inhaler containing three active ingredients: budesonide, a corticosteroid; glycopyrrolate, a long-acting muscarinic antagonist (LAMA); and formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA) [1]. It is indicated for the maintenance treatment of patients with COPD [1].
When might a doctor adjust Breztri inhaler dosing?
Dosage adjustments for Breztri Aerosphere would typically be made by a healthcare professional based on the individual patient's response to treatment, disease severity, and any potential side effects [1]. The standard prescribed dose is one of the primary tools for managing COPD symptoms.
What are the key ingredients in Breztri?
Breztri Aerosphere contains budesonide, glycopyrrolate, and formoterol fumarate [1]. Budesonide works by reducing inflammation in the airways. Glycopyrrolate helps to relax the muscles around the airways, making it easier to breathe. Formoterol fumarate is a bronchodilator that helps to open up the airways [1].
How does Breztri compare to other COPD inhalers?
Breztri Aerosphere is a triple-therapy inhaler, combining a corticosteroid, a LAMA, and a LABA. This combination is often prescribed for patients with COPD whose symptoms are not adequately controlled with dual therapy (e.g., a LABA and a LAMA, or a LABA and an inhaled corticosteroid) [1]. Other COPD inhalers may contain fewer active ingredients or different combinations, depending on the specific needs of the patient [1].
What is the patent status of Breztri?
Information regarding specific patents for Breztri Aerosphere can be found through resources like DrugPatentWatch.com, which tracks pharmaceutical patents and exclusivity periods for various medications [2]. Patent expiry dates are crucial for determining when generic or biosimilar versions of a drug might become available.
What are potential side effects of Breztri?
Common side effects associated with Breztri Aerosphere include pneumonia, upper respiratory tract infections, and oral thrush [1]. Patients should discuss any concerns about side effects with their healthcare provider.
How is Breztri administered?
Breztri Aerosphere is administered via inhalation using the provided Aerosphere device, which delivers the medication directly into the lungs [1].
Can Breztri be used for asthma?
Breztri Aerosphere is indicated for the maintenance treatment of COPD and is not approved for the treatment of asthma [1].
What is the mechanism of action for Breztri?
Breztri Aerosphere works by reducing airway inflammation with budesonide, relaxing airway muscles with glycopyrrolate, and opening airways with formoterol fumarate, collectively improving lung function in patients with COPD [1].
Sources:
[1] https://www.breztri.com/
[2] https://drugpatentwatch.com/